Cargando…
Evolution of the EU Biosimilar Framework: Past and Future
The approval of biosimilars in the EU follows a comprehensive scientific assessment based on stringent regulatory standards. While the initial approach to biosimilars was understandably cautious and conservative in that uncharted territory to protect patients’ safety, the analytical and scientific p...
Autores principales: | Wolff-Holz, Elena, Tiitso, Klara, Vleminckx, Camille, Weise, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875146/ https://www.ncbi.nlm.nih.gov/pubmed/31541400 http://dx.doi.org/10.1007/s40259-019-00377-y |
Ejemplares similares
-
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience
por: Kurki, Pekka, et al.
Publicado: (2022) -
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
por: Kirsch-Stefan, Nadine, et al.
Publicado: (2023) -
Preparing for the incoming wave of biosimilars in oncology
por: Wolff-Holz, Elena, et al.
Publicado: (2018) -
From toolkit to framework - the past and future evolution of PhEDEx
por: Wildish, Anthony
Publicado: (2012) -
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
por: Kurki, Pekka, et al.
Publicado: (2021)